Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 8, 2025 • 3:00 AM ET

Date/Time Source News Release
06/06/2025 08:05 AM EDT GlobeNewswire Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
05/28/2025 08:05 AM EDT GlobeNewswire Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
05/27/2025 08:05 AM EDT GlobeNewswire Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
05/22/2025 05:05 PM EDT GlobeNewswire Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
05/13/2025 08:05 AM EDT GlobeNewswire Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
05/06/2025 08:05 AM EDT GlobeNewswire Candel Therapeutics to Present at Upcoming Investor Conferences
04/23/2025 04:05 PM EDT GlobeNewswire Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
04/01/2025 08:01 AM EDT GlobeNewswire Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
03/26/2025 04:05 PM EDT GlobeNewswire Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
03/20/2025 08:00 AM EDT GlobeNewswire Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
Page

Additional News

As of June 8, 2025 • 3:00 AM ET

Date/Time Source News Release
06/02/2025 09:55 AM EDT Zacks Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?
05/29/2025 10:50 AM EDT Zacks CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
05/28/2025 03:31 PM EDT PRISM News Candel Wins FDA Recognition for Prostate Cancer Therapy Breakthrough
05/28/2025 10:27 AM EDT SeekingAlpha Candel gains after FDA RMT designation for lead asset
05/27/2025 04:13 AM EDT SeekingAlpha Candel Therapeutics: CAN-2409's Promising Progress Deserves An Upgrade
05/19/2025 10:00 AM EDT Zacks Best Momentum Stocks to Buy for May 19th
05/19/2025 07:49 AM EDT Zacks New Strong Buy Stocks for May 19th
05/18/2025 05:18 PM EDT Stock Traders Daily (CADL) Investment Report
05/16/2025 09:55 AM EDT Zacks Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know
05/13/2025 10:06 AM EDT Baystreet Cardell Flat on Q1
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.